Switching From PI to RALtegravir in HIV Stable Patients (SPIRAL)

This study has been completed.
Sponsor:
Information provided by:
Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT00528892
First received: September 10, 2007
Last updated: March 30, 2010
Last verified: May 2008

September 10, 2007
March 30, 2010
January 2008
March 2010   (final data collection date for primary outcome measure)
The proportion of patients with treatment failure (i.e.: those with viral failure, developing new CDC-C events, switching assigned treatment for any cause, withdrawing consent, being lost to follow-up or dying) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
The proportion of patients with treatment failure (i.e.: those with viral failure, developing new CDC-C events, switching assigned treatment for any cause, withdrawing consent, being lost to follow-up or dying) [ Time Frame: 48 weeks ]
Complete list of historical versions of study NCT00528892 on ClinicalTrials.gov Archive Site
The proportion of patients with viral failure while on assigned treatment (defined as two consecutive plasma HIV-RNA below detection limits) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
The proportion of patients with viral failure while on assigned treatment (defined as two consecutive plasma HIV-RNA below detection limits) [ Time Frame: 48 weeks ]
Not Provided
Not Provided
 
Switching From PI to RALtegravir in HIV Stable Patients
An Open-label, Randomized, 48-Week Study to Assess the Safety, Tolerability and Activity of Raltegravir When Replacing the Ritonavir-boosted PI Component of HAART in HIV-Infected Individuals With Viral Load Suppression on a Ritonavir-Boosted PI Containing Regimen.

The investigators hypothesis is that switching from a ritonavir-boosted PI to raltegravir may be associated with an at least non-inferior effectiveness, virological response and safety, and even a better tolerability profile with regard to lipid metabolism, insulin resistance, body fat distribution as compared with continuation of the baseline regimen in HIV-1 seropositive males or females at least 18 years of age and older on ritonavir-boosted PI plus at least 2 other drugs and plasma viral RNA below 50 copies/mL.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Raltegravir
    switching PI to raltegravir
  • Drug: boosted PI
    continue on boosted-PI
  • Experimental: 1
    Switch current boosted-PI to raltegravir 400 mg BID.
    Intervention: Drug: Raltegravir
  • Active Comparator: 2
    Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
    Intervention: Drug: boosted PI

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
282
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is a male or female at least 18 years of age.
  • Women of childbearing potential must have a negative serum pregnancy test (HCG) within 10 days prior to randomization into the study.
  • Patients must use adequate birth control measures (barrier method.)
  • Patients must be HIV 1 seropositive using standard diagnostic criteria.
  • Patients must have two plasma viral RNA measurements below detection limits with the routine ultrasensitive method used at each participating site (at least <50 copies/mL) within 180 days prior to randomization into this study.
  • Patients must be on continuous therapy with HAART consisting of a ritonavir-boosted protease-inhibitor (PI) and at least two other antiretroviral agents for at least 6 months prior to randomization into this study, with no planned drug changes in the following 12 months. Boosted PIs can be indinavir, fosamprenavir, saquinavir, lopinavir, atazanavir, tipranavir or darunavir.
  • Patients must be considered clinically stable, in the opinion of the investigator, at the time of entry into the study; i.e., clinical status and all chronic medications should be unchanged for at least 14 days prior to randomization. Patients currently receiving treatment for an opportunistic infection may be allowed into the study as long as the above criteria are met. Prophylaxis for opportunistic infections consistent with standard treatment is permissible. .
  • The following laboratory values must be obtained within 2-4 weeks of randomization into the study:

    • Hemoglobin >8.0 g/dL.
    • Absolute neutrophil count > 750/mm3
    • Platelet count > 50,000/ mm3
    • Creatinine < 2.0 mg/dL.
    • Transaminases (ALAT, ASAT) <5xULN

Exclusion Criteria:

  • Pregnancy or breast feeding or women planning pregnancy during the study duration.
  • Patients on ART regimens not likely to be maintained during the whole study duration
  • Prior use of HIV integrase inhibitors.
  • Use of any investigational agents (other than ART on expanded access programme) within 90 days of randomization.
  • Alcohol or substance abuse which in the opinion of the investigator would interfere with patient compliance or safety.
  • Patients with an active opportunistic infection or malignancy. Patients with a chronic, stable opportunistic infection will be allowed to enter this study.
  • Any condition or history of any illness which, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs to the patient.
  • Any patient with a diagnosis of visceral Kaposi's sarcoma. Patients with lymphedema secondary to cutaneous Kaposi's sarcoma, or with cutaneous or palatal Kaposi's sarcoma that has been treated with systemic immunosuppressive therapy must also be excluded.
  • Any patient with a diagnosis of acute hepatitis due to any cause. Patients with chronic hepatitis including chronic hepatitis B surface antigenemia chronic hepatitis C may enter the study as long as they have stable liver function tests and meet all inclusion criteria. Patients with acute exacerbations of chronic hepatitis are excluded.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00528892
SPIRAL, EUDRACT: 2007-003401-27
Yes
Jose M Gatell, Hospital Clinic barcelona
Hospital Clinic of Barcelona
Not Provided
Principal Investigator: Jose M Gatell, MD Hospital Clinic of Barcelona
Hospital Clinic of Barcelona
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP